Business Cards, Science and Personal Marketing

September 5th, 2014

The business card is a staple in most industries, it is how we show our face and who we are, but they are much less prevalent in science, particularly in the academic community. For many of us, the thought of handing out business cards congers up images of slimy douchebags at cheesy networking events. And when it comes to scientific events, everybody stares at you with a funny face. Yet, the reality is far from that fear.  The business card is a powerful professional tool that deserves serious consideration in all sectors, especially among scientists. Business cards are not just for business people. Consider the business card as a product of directed evolution in your career. Whether we’re aware of it or not, we spend a lot of time as scientists trying to figure out how to make our research stand out from the crowd, don’t have much time for networking needless to say distribute cards and make personal marketing.  We read the literature to figure out what’s been done in the past; we go to conferences to hear what others are working on and what is going on in our field; and we write grants targeting projects we think we can complete before anyone else.  It is indeed a stressful life with very few rewards and we all know it. That stuff is not easy at all. Yet, we often overlook the importance of standing out personally when meeting new colleagues, collaborators or potential employers. Luckily for us, most graduate students, postdocs and professors don’t use business cards.  Therefore, handing a card to a potential postdoctoral advisor will leave quite an impression.  In an industry like academic science where business cards are not provided to everyone upon hire, having one stands out. A card says you’re serious about your career path and take pride in doing it well. Building business cards involve two easy steps: 1) Design and 2) Production. For the first step of design, if you are in the academic sector, go to your Department and ask for one. Every institution is responsible to produce one to every scientist; even Ph.D. students and Post-Docs. If you are in the private sector, your boss needs to ask for a business card for you, so you can “show your face” when dealing with clients and/or in meetings. You can also design your own and there are plenty of websites and easy ways to do it. For example, BIZCard, Vistaprint and PrintsMadeEasy are three of the more well-known sites. Twenty bucks will get you more cards than you can give out and between frequent promotional deals on these sites, you can often get them much cheaper. I believe that scientists need and should have business cards. I have been to uncountable meetings and conferences where I would ask for somebody’s business card and the person would say “I do not have one. Do I need one?” These examples are mostly in the Academic Sector. Business cards represent your personal marketing and these days this could mean everything, even to get a new and better job. So, if you are a scientist, go ahead and make your own business card. It is about time!

Diabetes, Obesity and Genetics

July 18th, 2014

Doctors and researchers have found that obesity and diabetes are connected. People who are obese are at high risk for developing Type 2 diabetes (also known as “insulin-resistant” or “adult-onset” diabetes), particularly if a close family member is affected with diabetes. Therefore, it becomes very important to maintain a healthy body weight throughout your life in order to protect yourself from developing a chronic disease like diabetes. Researchers have also determined that only a slight predisposition for obesity is inherited. For example, the best way for children to avoid being overweight is to eat a diet that is balanced and is low in fat. This diet should consist of lots of fresh fruits and vegetables. Snacks like chips, cookies, ice cream, and soft drinks should be limited or eliminated. This may require a lifestyle change in a person’s life. It is very important that all children become involved in physical activities on a daily basis. Too many children spend their free time in front of computers, television, and video games, and this results in a growing number of kids who are obese and who will likely suffer medical consequences of obesity as adults. In order to become a diabetic, two factors need to be present. First, you need to inherit a predisposition to the disease, and second, the environment must trigger a response in your body. Your genes alone are not enough. This has already been shown in studies of groups of identical twins: when one of a pair of twins develops diabetes, there is only a slightly increased chance that the other sibling will develop the disease. Because identical twins are genetically similar, the environment of the individual might play a role in the development of diabetes. However, because both genetics and the environment are shared by family members, we recognize that people with a family history for diabetes have a greater risk for developing the disease. Another factor are epigenetic marks that change with diet and the environment. Molecular biology has shown the genetic and epigenetic basis for the development of both diseases. In recent years, expanded knowledge of the human genome has led to the development of new tools that facilitate the simultaneous analysis of thousands of genes for complex diseases. Researchers now rely on such tools in their search to uncover the gene networks associated to conditions such as diabetes and obesity. Today, geneticists use a number of forward approaches (for example, approaches that seek to find the genetic basis of a phenotype) in their efforts to understand how gene networks may contribute to these diseases. One such method is the genome-wide association study or GWAS; this high-throughput approach allows geneticists to scan the entire human genome in an unbiased manner, using statistical methods to determine associations between chromosomal loci and a given phenotype. For example, a recent genome-wide association study has reproducibly associated variants within introns of the gene FTO with increased risk for obesity and type 2 diabetes (for more information see “Obesity-associated variants within FTO form long-range functional connections with IRX3” by Smemo et al). Mutations in introns (noncoding regions) of the gene FTO have been widely investigated after genome-wide association studies revealed a strong link between FTO and diabetes. Yet, overexpressing or deleting FTO in animal models affects whole body mass and composition, not just fat, and experiments have failed to show that these obesity-linked introns affect the function of the FTO gene itself. Diabetes and obesity are directly involved since body fat and metabolism are strongly connected. This study showed that not just proteins are associated to obesity, but also non-coding regions such as enhancers and introns. Conformational changes in the DNA and epigenetics (mostly linked to diet and environmental exposure) might be the answer to better understand both diseases. However, until we completely uncover the mysteries of the genetics of metabolism, the best choice is to eat healthy and live well, independent on genetic predisposition and background. Like they say; you are what you eat. So, eat well and exercise.

 

 

 

Human Evolution and the Birth of Medicine

May 29th, 2014

There is no discussion: human and apes are close relatives with a common ancestor. Evolution studies confirm this hypothesis with different fossils differing in age with traces of genomic DNA and molecular features between these two species. Social science in apes also tells us that they are always in groups, have a structure of hierarchy and respect such as human societies. However, some questions remain, such as how primates deal with diseases and pain. In many traditional societies around the world people are very dependent in plants for both food and medicine. Close to a century ago, for example, a Tanzanian medicine man, Babu Kalunde, discovered an important treatment that saved the lives of many people in his village, who were suffering an epidemic of a dysentery-like illness. He learned about the potential medicinal value of a plant known as mulengelele by observing a sick animal eat the roots of the plant. This is a fact: animals in the jungle have to learn about medical plants and how to self-medicate. And this feature passes from generation to generation with parents teaching youngsters what to eat when they feel specific types of pain. Most of the details about two types of self-medicative behaviorin the great apes – namely, bitter-pith chewing and leaf swallowing – come from three study sites, Mahale and Gombe inTanzania and Kibale in Uganda, although these behaviors have been documented from 10 additional sites across Africa. The geographical, ecological, and climatic variation of these sites is great, ranging from low-elevation, moist tropical forest and woodland to forest. Such wide variation in geography, ecology, and climate where leaf swallowing and bitter-pith chewing are known to occur suggests that great ape populations elsewhere on the continent might also engage in these behaviors (for more information see “Self-Medicative Behavior in the African Great Apes: An Evolutionary Perspective into the Origins of Human Traditional Medicine” by Michael A. Huffman). Primates generally self-medicate with plants in the jungle and teach others what to eat depending on the pain. Specific plants for stomach pain are always shown to members of the community and offspring. The strong similarities in plant selection criteria among the African great apes in response to parasite infection and gastrointestinal upset, and the common use of some plants by chimpanzees and humans to treat such illnesses, are tantalizing evidence for the birth and evolution of medicine. Our earliest hominid ancestors may have exhibited some similarities in plant selection criteria with both extant apes and modern humans. Although the fossil record provides no direct evidence concerning specific feeding behavior and diet, it seems reasonable to hypothesize that early hominids would have displayed at least the range of extant ape self-medicative behavior. It appears that the fundamentals of perceiving the medicinal properties of a plant by its taste, smell, and texture have their roots deep in our primate history. A major turning point in the evolution of medicine is likely to have been the advent of language in early humans, which enabled people to share and pass on detailed experiences about plant properties and their effects against disease. That probably was the birth of medicine on earth. Since then, medicine continues to evolve, but if we go back to the jungle, primates use the same medical plants for generations to treat different types of pain. I believe we can learn a lot from them, especially to accelerate the development of new drugs for specific diseases. The bottom line is that primates are smarter than we think…

 

 

The Acquisition Boom in Technology

March 26th, 2014

In this post, I will leave science behind and discuss the technology “craziness” that has been happening. Billion Dollar acquisitions of companies that not even have revenue or profit. The Internet revolution now is eccentric and transforms youngsters with an app idea in millionaires and billionaires from day to night.  In less than 2 months, for example, Facebook acquired Whatsapp, the Drone maker Titan Aerospace and now the virtual reality company Oculus. A mix of software and hardware and new technologies are becoming the sexiest thing to acquire nowadays. Companies with tons of cash such as Facebook, Apple, Microsoft, Google, Yahoo and others can choose what to buy and how to buy. We are living in the new era of the internet. Working in Wall Street in the  financial district getting millions in investment deals is not the big American Dream anymore. The dream is to have an idea, build a start up and sell it for millions or billions of dollars to the big ones. Or even grow it to become the next Facebook or Google. One interesting case is Whatsapp, that was sold to Facebook by around 16 billion dollars. If you think about it, this is a lot of money, but strategically, it was a bold move. Whatsapp has no revenue whatsoever or even sell adds. It is simple, just a messaging app, but the number of Users builds its value. Let’s make the math: Facebook has around 1.2 billion users and of these probably millions use Whatsapp or have an account of it. However, millions that use Whatsapp (which is probably 200 million people) doesn’t have a Facebook account. Thus, Facebook indirectly bought new users that Whatsapp has to incorporate in its platform. I use Whatsapp to message people from family, friends and colleagues and see the trend in txt messaging. It is simple, useful, and the bottom line is that it does the job. Another example is Google buying Nest for 3 billion dollars. As its own early dive into wearables with Google Glass demonstrates, Google knows it can’t miss this next big leap in hardware. And Nest provides what they want in terms of geolocation of thermostats. The last big move occurred these days with Facebook buying the virtual reality company Oculus by 2 billion dollars. This is another example of a software company buying a hardware company. Facebook believes Oculus has the potential to be the most social platform ever by enabling sharing not just moments with your friends online, but entire experiences and adventures. This might be a competitive move by Facebook towards Google Glass Platform. Since after the burst of the bubble of the internet in the beginning of 2000, we have been watching another bubble of tech internet companies popping up and acquisitions of billions occurring. It has been all about strategy and new technology, not profits or revenue increase. The companies that are in the big “club” such as Facebook, Apple, Google, Yahoo and Microsoft are positioning themselves in a competitive scenario. The only question is who is going to be successful in the long run with these acquisitions. There is a promising future in the tech sector. Are we close to the movie “Minority Report” with virtual reality? Facebook believes so. We will see.

“Dallas Buyers Club” and HIV testing

February 3rd, 2014

What would you do if you were tested positive for HIV in a routine blood exam? Well, this question came up after I saw the movie Dallas Buyers Club. The movie portrays the life of Ron Woodroof, who was a Texas cowboy and drug user and was diagnosed with AIDS in the 1980s. He was initially given 30 days to live, but Woodroof (portrayed by actor Matthew McConaughey) begins taking azidothymidine (AZT), the only HIV drug legally available in America at that time. Woodroof goes on to travel the world, searching for medications that will keep him alive, and as a result, the Dallas Buyers Club is formed.  With the help of a doctor and another patient played by Jared Leto as a transsexual, Woodroof begins selling smuggled drugs out of a motel in Dallas, providing HIV-positive patients with alternative forms of treatment for their disease, since the FDA was still testing the drugs that are currently used. Interestingly, the storyline closely reflects the real life events of Ron Woodroof and provides a great example of how patient advocacy hastened the development of effective HIV medications during the 80s. I watched the movie and it was clear how the process of drug approval and lab testing is still rudimentary. Coming back to my question in the beginning of this blog post, what if your HIV test comes back positive? Well, what if I say that the standard tests done for HIV have problems with numerous false-positives? The main and most widely test used is an immunoassay called ELISA that measures antibodies against the virus. However, viruses are very similar and have building blocks or proteins that look alike. So, when you measure antibodies against a response of the human body for a viral infection, false-positives can occur. Indeed, I am writing this post to give people awareness that, for example, flu vaccination could cause a false positive for HIV. Like I said, the viruses are very similar. The HIV GP160 protein exists in several viruses and has a lot of similar regions (see more at this report on the New England Journal of Medicine “Influenza Vaccination and False Positive HIV Results”). This protein is present in other virions too, especially a variety of flu related viruses. Thus, vaccination against any type of flu could generate a cross-reaction in the aforementioned immunoassay. In fact, there are several reports and groups of discussion online in which the most discussed subject is a false positive test result for HIV. Yes, that is scary and weird, but it is more common that we imagine. Given the escalating international awareness of various influenza strains and flu vaccination, it is very important for clinicians and patients to keep in mind that influenza vaccination may cause cross-reactivity with HIV antibody assays. The time course for such cross-reactivity remains mostly uncertain, but could be for months. If your HIV test was positive, take into account this possibility and ask for the use of a nucleic acid amplification test instead of the “Western blot” assay to confirm the enzyme immunoassay. People should and need to be aware of that. The movie Dallas Buyers Club just reminded me how science and research can be misleading within its own “rules”. Ron Woodroof tried to overcome these rules to save lives and himself. We all need to take care of ourselves, of course, using the law to do it. The take home message is that we still do not understand enough about the biology of viruses and confusions such as the one I discuss here could happen. So be aware!

 

 

 

A Digital Revolution in Healthcare?

January 24th, 2014

Recent advances in information technology have opened an exciting new frontier. A convergence is taking place between medicine and wireless technology, making it possible to change the way medicine and healthcare delivery are managed. In the coming years, this digital revolution in medicine could have far-reaching and more dramatic implications, changing the face of healthcare around the world. Mobile sensors and advanced processors are already enhancing doctors understanding of their patients signs and symptoms, leading to more personalized and effective ways to maintain health, detect problems, and treat illness. In our increasingly connected world, where more than 6 billion people have access to mobile devices, this individualized healthcare data has the potential to be collected and distributed nearly instantly, resulting in improved care for people of all ages, in every area of the world, who suffer from virtually any disease, from diabetes to Alzheimer’s to breast cancer. The two major drivers of the increased interest in digital healthcare are both the emergence of online networks (mainly because the internet is getting faster) and big data accumulation, mostly coming from medical records and scientific research (for more information see my recent article “The impact of online networks and big data in Life Sciences” at the Social Networking Journal). In fact, there are already more than 10,000 medical and healthcare apps available for download from Apple iTunes store and this is the third-fastest growing category among iPhone and Android users, showing no sign of slowing with the mobile health market estimated to grow ten times from U$1.2 billion in 2011, to U$12 billion in 2018. The major barriers to speed up the application of digitalized information in healthcare are the privacy of the data and regulation hurdles (see more at my article “Big Data in Biomedicine” published on Drug Discovery Today). However, I believe that technology always overcomes all barriers, especially when big amounts of cash are been thrown in a specific sector such as healthcare. For example, health is the number two most searched subject on the web.The mobile industry impacts in this change, mainly because almost all humans on earth now own a smartphone with internet and search capabilities.Ultimately, this revolution will be driven by “machine to machine” interactions. For this new digital era to be truly transformational, apps need to transmit information directly to healthcare providers. This will allow the healthcare systems to not only react, but to predict health outcomes based on a patient’s personal information. mHealth or mobile Health will allow communication and monitoring to take place like never before. Your body will talk to the healthcare system without you even knowing it. This new revolution started now and won’t stop. If it is to save more lives and so people could live more and better, so be it! (Image Source: Huffingtonpost)

Cancer – many diseases in one?

November 18th, 2013

Cancer is a disease of the cells. The body is made up of a community of individual cells, each of which has a specific job to ensure that the community functions correctly. Liver cells must detoxify the fluids of the body, lung cells must exchange oxygen and carbon dioxide from the blood, and skin cells must separate the outside world from the inside of our body. In addition to performing their assigned jobs, cells are also good citizens. Cells respect the space of the other cells around them and support the healthiness of those cells. Occasionally, cells begin to grow in an uncontrolled fashion, causing many problems for the body. Cancer is a disease of uncontrolled cell growth or proliferation. Cancer cells are no longer good citizens. For instance, a liver cell that becomes cancerous no longer does its job of detoxifying the body. In addition, cancer cells do not respect their neighboring cells and will crowd them out of existence. We always had this concept that is still used in pathology today that each cancer type refers to the tissue and cell type of origin. In that case, breast cancers would emerge from the breast cells and have their original characteristics. It turns out that cancer is a combination of many different diseases in one. Cancer is not a single disease, but literally hundreds of different diseases. This is of great practical importance to both physicians and patients, because different cancers have to be treated differently having different outcomes for the patients. In this regard, recent studies have shown that we should classify and also treat tumors mainly based on the mutations that they carry other than the tissue of origin (see more in the article “Mutational landscape and significance across 12 major cancer types” by Kandoth et al. on Nature). Multiple genes are defective in cancers. Cancer does not occur from a single gene mutation in a single gene. Instead, the development of cancer involves multiple mutations within several key genes, including mutations in proto-oncogenes, tumor suppressor genes, DNA repair genes, etc. Researchers recently pointed out that we should start treating tumors based on their genetic and genomic profiles and landscape. These findings lay the groundwork for the development of personalized therapies. In addition, it is clear that pathways of genes should be the focus of treatment (see the comment “Herceptin pioneer’s life science innovation: Cancer pathways should be treatment focus” at MedCity News). These pathways of genes represent the driver defects that could be the cause of the disease, thus providing windows of opportunity in therapeutics (see more in the article “Comprehensive identification of mutational cancer driver genes across 12 tumor types” by Tamborero et al. on Nature). In the future, cancer will be a chronic disease controlled by an array of medicines each targeting a defective pathway of that specific tumor. Cancers will soon be classified based on their genetic profiles instead of the tissue of origin. Drug companies are already starting to adapt to this trend and new cocktails of more targeted therapies are on the horizon (Image Source: FOX News).

 

 

Can Google Help Us Extend Lifespan?

October 7th, 2013

If everyone on the Forbes company list and the world’s millionaires and billionaires simultaneously (and tragically) got cancer, or Parkinson’s (or any other complex disease), the world would probably be well on its way to finding a cure for these illnesses, thanks to the enormous wealth that would be incentivized to back those efforts (check the article “WTF Is Calico, And Why Does Google Think Its Mysterious New Company Can Defy Aging?” for more information). Finding a cure for an intractable disease requires time, enormous amounts of human and financial capital, cooperation and a lot of basic and translational research – and at least a few public-private partnerships. It’s costly, it is complex and it’s messy. Nobody thinks on how to tackle these diseases and find better treatments or even a cure; the truth is that until you get sick you don’t really care. This is why Calico, Google’s newest mad science project, is potentially interesting and it was all over the news a couple of weeks ago. Calico is a healthcare company that Google is investing in that will be able to use all the crawled information in Google’s servers and databases to seek for valuable clues for treating diseases and eventually beating death. Crunching data into actionable information is Google’s future with the driverless cars, Google Glass and other “crazy” projects from the arm of Google Labs named Google [X] that Sergey Brin leads. Calico can use Google’s reach to make health data available, actionable, organize it and create a community around it, opening unprecedented opportunities for patient engagement with health data. Big Data analytics in healthcare is having a lot of attention right now and Google couldn’t be behind. Some say this is the boldest bet yet (see more at the article “Google vs. Death” in the Cover of TIME Magazine). Calico represents the company’s largest healthcare initiative since Google Health sprinted its way into obscurity and was shut down. Larry Page says he wants to solve cancer, but as a researcher in oncology for a decade, I would say this problem is more complex than the surface of it reveals. I really think it is amazing what Google has done and it is doing, and believe it takes a company with so many resources to attack and find cures for diseases such as cancer. There are many components in Google’s history indicating that they will be able to at least help: 1) they have access to tons of data points, especially published data from scientific journals; 2) Google may not solve death or help us beat it but at least it will help us understand the aging process better using our own data in the web using time as a variable; 3) at the very least it brings all kinds of attention from industry and people, especially those already sick (see more at “What Google’s Calico Means For Healthcare”).There is still a significant gap between researchers and entrepreneurs. However, at the same time, there are now more opportunities than ever before for both sides to team up to make technological breakthroughs in healthcare, and, in turn, making those breakthroughs more accessible to the general public. So, I believe that if Calico can’t give us immortality and cure complex diseases, at least it is bringing the focus of the industries to healthcare, one of the sectors that did not have many technological breakthroughs in years. Maybe we should focus our ideas and ventures in the healthcare sector like Google is starting to do. If they are successful, we all win. But if they are not, it is just another “crazy” project from Google [X] labs that failed. We will see. (Image Source: TIME Magazine)

Chicago – an Emerging Biotech Hub

September 3rd, 2013

Article by Charlotte Chen, Ph.D. Candidate at Northwestern University

CHICAGO – While Boston and Silicon Valley seem to be the most visible biotech hubs in the US, the nation’s best kept secret in biotech may just be in the Midwest. Indeed, in 2011, the eight-state Midwestern super cluster – Illinois, Ohio, Wisconsin, Minnesota, Michigan, Indiana, Missouri, Kansas, Iowa – employed over 120,000 more employees than either California or the East Coast (Ernst & Young, 2013), with more than 377,900 employees in over 16,800 establishments. The key player in The Midwest Super Cluster is undeniably Illinois. The state is home to more than 3,500 biotech companies that employ around 81,000 people, with a gross economic output of around $98.6 billion (Illinois Government News Network, 2013). Chicago sits at the center of all this, with some of the best medical research universities in the Midwest and a vibrant biotech industry. In the Chicago metropolitan area alone, around 45,000 employees work in about one thousand biotech companies. Some big-name biotechnology companies headquartered in the greater Chicago area include Abbott Laboratories, credited with developing the world’s first HIV blood screening test in 1985 and which now has 90,000 employees across 130 countries, and Baxter Healthcare, known for its hemophilia, renal disease, and immune disorder therapies, which brought in $10.4 billion in earnings in 2006. So why does Chicago get overshadowed by its counterpart biotech hubs on the East and West coasts? One factor could be a lack of entrepreneurial tradition in biotech. Silicon Valley and Boston have created an industry culture that embraces risk-taking, and entrepreneurs expect to fail a number of times before hitting a winning idea. While the Midwest has all the expertise to drive biotech innovation, this entrepreneurial spirit is only recently beginning to flourish. In 2012, $150 million venture dollars went into biotech startups in Chicago (City of Chicago, 2013), versus $1 billion in Silicon Valley and $860 million in Boston (MIT Technology Review, 2013). Hoping to raise Chicago’s profile in the biotech world, state and city policymakers recently established two new biotech incubators, which are set to open in Chicago within the next year. The first of these incubators is the Health, Technology, and Innovation (HTI) facility, created by Governor Pat Quinn in partnership with the University of Illinois at Chicago, with the goal of boosting Illinois’ economy. HTI is located at Chicago Technology Park in the city’s Near West Side, within the Illinois Medical District and in close proximity to the University of Chicago’s Pritzker School of Medicine, and is set to open in the summer of 2013. The State of Illinois and UIC split the bill equitably, each contributing $1.7 million for a total of $3.4 million in initial funding. HTI will provide wet and dry lab space and office space to tenants, as well as access to a network of scientists, investors, and other leaders in the biotech industry. The incubator is intended to provide a low-risk environment for academic researchers to bring their ideas out of university labs for the first time, and to see whether they can become successful ventures. The City of Chicago is also throwing its support behind the biosciences industry. Mayor Rahm Emanuel recently announced plans to construct a biotech incubator in downtown Chicago, set to open in 2014. With this additional facility, the city hopes to increase Chicago’s national profile as a biotechnology innovation hub. The new incubator will provide a space for researchers from Chicago’s top universities to collaborate with investors and partners in industry to develop discoveries from academic research with commercial potential. It will also provide a downtown presence for major biotechnology companies in the area, most of which are located in the Northern Chicago suburbs. This new incubator will be well-supported through access to professionals with business expertise, such as Chicago Innovation Mentors and ChicagoNEXT. Chicago Innovation Mentors is an organization that pairs university faculty with industry mentors to accelerate the formation of new biotechnology ventures, and its members include the University of Chicago, Northwestern University, the University of Illinois at Chicago, and iBio Institute/PROPEL. ChicagoNEXT is an organization created by World Business Chicago to accelerate innovation in clean tech, web and mobile technology, and biosciences. The new biotech is roughly modeled on 1871, an incubator for IT and digital startups in downtown Chicago. Chicago is also breeding homegrown entrepreneurial talent. The University of Chicago’s Polsky Center for Entrepreneurship offers entrepreneurship courses, a student entrepreneurship club, business plan competitions, and entrepreneurship mentoring to its students, as does Northwestern’s Farley Center for Entrepreneurship and Innovation. The University of Illinois at Chicago offers a Bachelors in Entrepreneurship, and its Liautaud Graduate School of Business offers an entrepreneurship program. While established biotech companies are by no means a new presence in Chicago, a nascent culture of innovation is emerging in the style of Silicon Valley and Boston. Perhaps with all these efforts to spark biotech innovation in Chicago, the Midwest’s “best kept secret” in biotech will be unveiled soon. (Chicago’s Skyline Image Source: Wikimedia Commons)

See original article published at the Roundtable Review

Science gets a little help from the Crowd

August 11th, 2013

The basic definition of crowdsourcing says that it is a process that involves outsourcing tasks to a distributed group of people. These tasks could be online or offline, paid or for free, and they are outsourced to an undefined public. So the idea behind crowdsourcing is that the more people working on a specific project, the better, faster and more varied results will be achieved. The two common functions offered by crowdsourcing are the distribution of large sets of work, and the democratization of opinion gathering, since different groups of people will be able to participate. Interestingly, crowdsourcing channels the experts’ desire to solve a problem freely sharing the answer with everyone. Different projects in a variety of fields have been using crowdsourcing. Examples include projects like GalaxyZoo in astronomy and Encyclopedia of Life in biology. Even the toy company LEGO had its own crowdsourcing project to get input on the most common designs made by customers using their building blocks. In a similar manner, crowdsourcing has been pointed out as a solution to seek for drugs that are effective for specific diseases using big data analytics. The same way crowdsourcing uses “crowds” to solve problems, crowdfunding raises money for projects from different people, mostly via web. It gives everybody the ability to raise money from a collective group of people who are connected through the internet and want to support a specific project. Successful crowdfunding platforms include Kickstarter, Indiegogo and RocketHub. However, can we use both crowdsourcing and crowdfunding in Scientific Projects? Well, since science is a very closed community with several “rules”, I would say at first that it would never work. But, recent cuts in federal funding are helping it become reality. Platforms such as Microryza, founded by two University of Washington graduates in Seattle, is one of the first crowdfunding sites for science. About 80 projects have already raised a combined U$ 200,000 through Microryza. Another specific example is uBiome, which is using crowdsourcing and crowdfunding to sequence and catalogue the microbiome of different people that is willing to participate in their project. Science is typically funded by peer-reviewed grants, however with the advent of the internet, new technologies and social networks, general people is getting the power to do the same. The scientific field could gain a lot from these types of approaches. The only risk is that the public will fund projects that are around themes or topics that they can more readily understand, such as research into Alzheimer’s disease, cancer, diabetes, while other projects may be ignored. We will see. I think that alternatives for federal and governmental funding such as those are really warranted. The use of “crowds” and the general public could be a nice and socialized solution to solve the funding problem in Science.